Overview

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.
Phase:
Phase 3
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Merck, S.L., Spain
Treatments:
Hormones